564 related articles for article (PubMed ID: 33358977)
1. Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.
Park KS; Bazzill JD; Son S; Nam J; Shin SW; Ochyl LJ; Stuckey JA; Meagher JL; Chang L; Song J; Montefiori DC; LaBranche CC; Smith JL; Xu J; Moon JJ
J Control Release; 2021 Feb; 330():529-539. PubMed ID: 33358977
[TBL] [Abstract][Full Text] [Related]
2. A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.
Steinbuck MP; Seenappa LM; Jakubowski A; McNeil LK; Haqq CM; DeMuth PC
Sci Adv; 2021 Feb; 7(6):. PubMed ID: 33547083
[TBL] [Abstract][Full Text] [Related]
3. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
[TBL] [Abstract][Full Text] [Related]
4. SMART-lipid nanoparticles enabled mRNA vaccine elicits cross-reactive humoral responses against the omicron sub-variants.
Mahalingam G; Rachamalla HK; Arjunan P; Karuppusamy KV; Periyasami Y; Mohan A; Subramaniyam K; M S; Rajendran V; Moorthy M; Varghese GM; Mohankumar KM; Thangavel S; Srivastava A; Marepally S
Mol Ther; 2024 May; 32(5):1284-1297. PubMed ID: 38414245
[TBL] [Abstract][Full Text] [Related]
5. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
[TBL] [Abstract][Full Text] [Related]
6. Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys.
Li H; Guo L; Zheng H; Li J; Zhao X; Li J; Liang Y; Yang F; Zhao Y; Yang J; Xue M; Zuo Y; Zhou J; Chen Y; Yang Z; Li Y; Jin W; Shi H; He Z; Li Q; Liu L
Bioconjug Chem; 2021 May; 32(5):1034-1046. PubMed ID: 33951913
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the immunogenicity of gold nanoparticles conjugated RBD with Freund's adjuvant as a potential vaccine against SARS-CoV-2.
Moshref Javadi M; Taghdisi Hosseinzadeh M; Soleimani N; Rommasi F
Microb Pathog; 2022 Sep; 170():105687. PubMed ID: 35917987
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice.
Barbey C; Su J; Billmeier M; Stefan N; Bester R; Carnell G; Temperton N; Heeney J; Protzer U; Breunig M; Wagner R; Peterhoff D
Eur J Pharm Biopharm; 2023 Nov; 192():41-55. PubMed ID: 37774890
[TBL] [Abstract][Full Text] [Related]
9. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
[TBL] [Abstract][Full Text] [Related]
10. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
Front Immunol; 2022; 13():974364. PubMed ID: 36159845
[TBL] [Abstract][Full Text] [Related]
11. Lipid Nanoparticle RBD-hFc mRNA Vaccine Protects hACE2 Transgenic Mice against a Lethal SARS-CoV-2 Infection.
Elia U; Rotem S; Bar-Haim E; Ramishetti S; Naidu GS; Gur D; Aftalion M; Israeli M; Bercovich-Kinori A; Alcalay R; Makdasi E; Chitlaru T; Rosenfeld R; Israely T; Melamed S; Abutbul Ionita I; Danino D; Peer D; Cohen O
Nano Lett; 2021 Jun; 21(11):4774-4779. PubMed ID: 34032435
[TBL] [Abstract][Full Text] [Related]
12. Nano-carrier DMSN for effective multi-antigen vaccination against SARS-CoV-2.
Sun P; Cheng B; Ru J; Li X; Fang G; Xie Y; Shi G; Hou J; Zhao L; Gan L; Ma L; Liang C; Chen Y; Li Z
J Nanobiotechnology; 2024 Jan; 22(1):11. PubMed ID: 38167103
[TBL] [Abstract][Full Text] [Related]
13. RBD decorated PLA nanoparticle admixture with aluminum hydroxide elicit robust and long lasting immune response against SARS-CoV-2.
Meena J; Singhvi P; Srichandan S; Dandotiya J; Verma J; Singh M; Ahuja R; Panwar N; Wani TQ; Khatri R; Siddiqui G; Gupta A; Samal S; Panda AK
Eur J Pharm Biopharm; 2022 Jul; 176():43-53. PubMed ID: 35589003
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
[TBL] [Abstract][Full Text] [Related]
15. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.
Kang YF; Sun C; Zhuang Z; Yuan RY; Zheng Q; Li JP; Zhou PP; Chen XC; Liu Z; Zhang X; Yu XH; Kong XW; Zhu QY; Zhong Q; Xu M; Zhong NS; Zeng YX; Feng GK; Ke C; Zhao JC; Zeng MS
ACS Nano; 2021 Feb; 15(2):2738-2752. PubMed ID: 33464829
[TBL] [Abstract][Full Text] [Related]
16. Immune response induced by oral administration with a Saccharomyces cerevisiae-based SARS-CoV-2 vaccine in mice.
Gao T; Ren Y; Li S; Lu X; Lei H
Microb Cell Fact; 2021 May; 20(1):95. PubMed ID: 33952256
[TBL] [Abstract][Full Text] [Related]
17. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.
Tang J; Zhang N; Tao X; Zhao G; Guo Y; Tseng CT; Jiang S; Du L; Zhou Y
Hum Vaccin Immunother; 2015; 11(5):1244-50. PubMed ID: 25874632
[TBL] [Abstract][Full Text] [Related]
18. A SARS-CoV-2 nanoparticle vaccine based on chemical conjugation of loxoribine and SpyCatcher/SpyTag.
Yan W; Yu W; Shen L; Xiao L; Qi J; Hu T
Int J Biol Macromol; 2023 Dec; 253(Pt 5):127159. PubMed ID: 37778577
[TBL] [Abstract][Full Text] [Related]
19. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
Jeong H; Choi YM; Seo H; Kim BJ
Front Immunol; 2021; 12():637654. PubMed ID: 33732258
[TBL] [Abstract][Full Text] [Related]
20. Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants.
van Oosten L; Altenburg JJ; Fougeroux C; Geertsema C; van den End F; Evers WAC; Westphal AH; Lindhoud S; van den Berg W; Swarts DC; Deurhof L; Suhrbier A; Le TT; Torres Morales S; Myeni SK; Kikkert M; Sander AF; de Jongh WA; Dagil R; Nielsen MA; Salanti A; Søgaard M; Keijzer TMP; Weijers D; Eppink MHM; Wijffels RH; van Oers MM; Martens DE; Pijlman GP
mBio; 2021 Oct; 12(5):e0181321. PubMed ID: 34634927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
